Evaluation of the efficacy, tolerability, and safety of 7 days of treatment with GRT6010 or pregabalin in comparison to placebo in subjects with peripheral neuropathic pain.

Trial Profile

Evaluation of the efficacy, tolerability, and safety of 7 days of treatment with GRT6010 or pregabalin in comparison to placebo in subjects with peripheral neuropathic pain.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2014

At a glance

  • Drugs GRT 6010 (Primary) ; Pregabalin
  • Indications Neuropathic pain; Postherpetic neuralgia
  • Focus Therapeutic Use
  • Sponsors Grunenthal
  • Most Recent Events

    • 01 Oct 2014 Status changed from completed to discontinued, as per ClinicalTrials.gov record.
    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Mar 2012 Additional trial location (Italy) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top